.jpg?w=340&itok=1GaUX779 "EPR in healthcare news."){kind=icon}
Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
Regulatory authorities have made it clear that streamlining biosimilar development is a priority, following the example of the EMA and FDA in reducing the requirements for comparative efficacy studies. Read this article to understand the recent changes and their impact.
-
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
This article explores practical actions for manufacturing and chemistry, manufacturing, and controls (CMC) teams to align with Q5A(R2)’s updated guidance and stay ahead of the rapidly changing viral safety environment. Implemented well, these actions can shorten testing timelines and strengthen assurance of participant safety.
-
Reimagining vaccine development with AI
Explore how AI is accelerating vaccine development, improving speed, precision, and global readiness.
-
.jpg?w=545&itok=B57ydSJe "EPR in healthcare news.")
Harnessing AI for more efficient clinical trials
ICON’s SVP of Enterprise AI, Tony Clarke, joined a panel of industry leaders at the recent European Pharmaceutical Review’s webinar, “Harnessing AI for more efficient clinical trials” to share his perspective on how AI is being applied to improve trial efficiency, insight generation and operational execution.
-
AI tools life sciences companies
This BioSpectrum Asia piece highlights the AI tools leading organisations are already putting to work—an important look at where practical adoption is delivering real impact across the industry with contributions from Tony Clarke, SVP of Enterprise AI at ICON.
-
ICON expands early phase capabilities
Opens new Clinical Research Unit and satellite outpatient clinics.
-
ICON opens new Texas clinical research unit
ICON boosts early phase trials with new San Antonio facility, enhancing participant care and operational efficiency.
-
ICON opens early-phase research unit in San Antonio, plus satellite clinics to grow trial capabilities
The San Antonio facility includes a clinic, pharmacy, laboratory and investigational product handling services intended to improve dosing efficiency, protocol modifications and delivery timelines for sponsors.
-
Aging with HIV: What the next major challenge is for drug development
As people with HIV live longer due to ART, new challenges are emerging. Aging with HIV is linked to higher risks of comorbidities, chronic inflammation, and drug interactions, while gaps in clinical trial inclusion and care models highlight the need for more integrated, patient-centered treatment strategies.
-
Banyan BioInnovations debuts with $100M+ and ICON
A new biotech investment firm launches with more than $100 million in initial commitments from life science investors. ICON is both a strategic collaborator and an equity investor.
